Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of subcutaneous efgartigimod PH20 in ocular myasthenia gravis
CTR20244895Phase 3Active
- Sponsor
- argenx
- Start
- Feb 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Efgartigimod PH20 SC with Placebo PH20 SC (2 arms). Primary endpoint: Change in MGII (PRO) ocular score from baseline to Day 29 (Part A). Started Feb 2025; status: active.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20244895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244895.